(XYL) Xylem - Overview
Stock: Pumps, Meters, Controls, Filtration, Analytics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.19% |
| Yield on Cost 5y | 1.68% |
| Yield CAGR 5y | 9.33% |
| Payout Consistency | 100.0% |
| Payout Ratio | 43.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.6% |
| Relative Tail Risk | -7.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.32 |
| Alpha | -3.20 |
| Character TTM | |
|---|---|
| Beta | 0.857 |
| Beta Downside | 0.890 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.73% |
| CAGR/Max DD | 0.41 |
Description: XYL Xylem January 28, 2026
Xylem Inc. (NYSE: XYL) designs, manufactures, and services engineered water-related products for utility, industrial, residential, and commercial markets worldwide. The firm operates through four segments: Water Infrastructure; Applied Water; Measurement & Control Solutions; and Water Solutions & Services, delivering pumps, treatment equipment, smart meters, analytics software, and a suite of maintenance and remediation services under brands such as Flygt, Sensus, and Bell & Gossett.
In its most recent fiscal year (FY 2024), Xylem reported total revenue of $5.6 billion, up 6 % year-over-year, with the Measurement & Control Solutions segment posting a 12 % revenue growth driven by expanding smart-meter deployments. Adjusted EBITDA margin held at 15 %, and free cash flow reached $620 million, supporting continued dividend payouts and share-repurchase activity.
Key macro drivers remain robust: the global water-infrastructure market is projected to expand at a 5 % compound annual growth rate through 2030 as governments increase capital spending on climate-resilient water systems. Additionally, the U.S. EPA’s tightening of wastewater discharge standards is accelerating demand for Xylem’s advanced treatment and monitoring solutions, particularly in the Applied Water segment.
Given the breadth of Xylem’s product portfolio and its exposure to rising water-infrastructure spend, a deeper dive into segment-level forecasts may help assess upside potential-ValueRay’s analytics platform provides that granular view for further research.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 948.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.19 > 1.0 |
| NWC/Revenue: 24.42% < 20% (prev 23.28%; Δ 1.14% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.27b > Net Income 948.0m |
| Net Debt (898.0m) to EBITDA (1.79b): 0.50 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (244.1m) vs 12m ago 0.14% < -2% |
| Gross Margin: 38.23% > 18% (prev 0.37%; Δ 3786 % > 0.5%) |
| Asset Turnover: 53.35% > 50% (prev 52.50%; Δ 0.85% > 0%) |
| Interest Coverage Ratio: 38.12 > 6 (EBITDA TTM 1.79b / Interest Expense TTM 32.0m) |
Altman Z'' 2.55
| A: 0.13 (Total Current Assets 4.44b - Total Current Liabilities 2.27b) / Total Assets 17.30b |
| B: 0.20 (Retained Earnings 3.47b / Total Assets 17.30b) |
| C: 0.07 (EBIT TTM 1.22b / Avg Total Assets 16.67b) |
| D: 0.55 (Book Value of Equity 3.24b / Total Liabilities 5.85b) |
| Altman-Z'' Score: 2.55 = A |
Beneish M -3.04
| DSRI: 1.00 (Receivables 1.80b/1.71b, Revenue 8.89b/8.42b) |
| GMI: 0.97 (GM 38.23% / 36.97%) |
| AQI: 1.00 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.06 (Revenue 8.89b / 8.42b) |
| TATA: -0.02 (NI 948.0m - CFO 1.27b) / TA 17.30b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of XYL shares?
Over the past week, the price has changed by +3.08%, over one month by +0.56%, over three months by -5.20% and over the past year by +9.43%.
Is XYL a buy, sell or hold?
- StrongBuy: 9
- Buy: 5
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the XYL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 167.2 | 17.6% |
| Analysts Target Price | 167.2 | 17.6% |
| ValueRay Target Price | 154.3 | 8.6% |
XYL Fundamental Data Overview February 05, 2026
P/E Forward = 25.3807
P/S = 3.7933
P/B = 3.0389
P/EG = 2.1423
Revenue TTM = 8.89b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.79b USD
Long Term Debt = 1.91b USD (from longTermDebt, last quarter)
Short Term Debt = 176.0m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 898.0m USD (from netDebt column, last quarter)
Enterprise Value = 34.64b USD (33.74b + Debt 2.09b - CCE 1.19b)
Interest Coverage Ratio = 38.12 (Ebit TTM 1.22b / Interest Expense TTM 32.0m)
EV/FCF = 37.44x (Enterprise Value 34.64b / FCF TTM 925.0m)
FCF Yield = 2.67% (FCF TTM 925.0m / Enterprise Value 34.64b)
FCF Margin = 10.40% (FCF TTM 925.0m / Revenue TTM 8.89b)
Net Margin = 10.66% (Net Income TTM 948.0m / Revenue TTM 8.89b)
Gross Margin = 38.23% ((Revenue TTM 8.89b - Cost of Revenue TTM 5.49b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 38.77%)
Tobins Q-Ratio = 2.00 (Enterprise Value 34.64b / Total Assets 17.30b)
Interest Expense / Debt = 0.29% (Interest Expense 6.00m / Debt 2.09b)
Taxrate = 23.91% (71.0m / 297.0m)
NOPAT = 928.4m (EBIT 1.22b * (1 - 23.91%))
Current Ratio = 1.96 (Total Current Assets 4.44b / Total Current Liabilities 2.27b)
Debt / Equity = 0.19 (Debt 2.09b / totalStockholderEquity, last quarter 11.21b)
Debt / EBITDA = 0.50 (Net Debt 898.0m / EBITDA 1.79b)
Debt / FCF = 0.97 (Net Debt 898.0m / FCF TTM 925.0m)
Total Stockholder Equity = 10.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.69% (Net Income 948.0m / Total Assets 17.30b)
RoE = 8.67% (Net Income TTM 948.0m / Total Stockholder Equity 10.93b)
RoCE = 9.50% (EBIT 1.22b / Capital Employed (Equity 10.93b + L.T.Debt 1.91b))
RoIC = 7.18% (NOPAT 928.4m / Invested Capital 12.93b)
WACC = 8.55% (E(33.74b)/V(35.83b) * Re(9.07%) + D(2.09b)/V(35.83b) * Rd(0.29%) * (1-Tc(0.24)))
Discount Rate = 9.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.54%
[DCF Debug] Terminal Value 79.48% ; FCFF base≈886.2m ; Y1≈1.09b ; Y5≈1.86b
Fair Price DCF = 112.5 (EV 28.28b - Net Debt 898.0m = Equity 27.38b / Shares 243.5m; r=8.55% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 18.03 | EPS CAGR: -37.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.92 | Revenue CAGR: 15.46% | SUE: 0.87 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=+0.001 | Revisions Net=-1 | Analysts=13
EPS next Year (2026-12-31): EPS=5.55 | Chg30d=-0.005 | Revisions Net=-2 | Growth EPS=+9.6% | Growth Revenue=+3.6%